Your browser doesn't support javascript.
loading
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Malorni, Luca; Tyekucheva, Svitlana; Hilbers, Florentine S; Ignatiadis, Michail; Neven, Patrick; Colleoni, Marco; Henry, Stéphanie; Ballestrero, Alberto; Bonetti, Andrea; Jerusalem, Guy; Papadimitriou, Konstantinos; Bernardo, Antonio; Seles, Elena; Duhoux, Francois P; MacPherson, Iain R; Thomson, Alastair; Davies, David Mark; Bergqvist, Mattias; Migliaccio, Ilenia; Gebhart, Géraldine; Zoppoli, Gabriele; Bliss, Judith M; Benelli, Matteo; McCartney, Amelia; Kammler, Roswitha; De Swert, Heidi; Ruepp, Barbara; Fumagalli, Debora; Maibach, Rudolf; Cameron, David; Loi, Sherene; Piccart, Martine; Regan, Meredith M.
Afiliación
  • Malorni L; "Sandro Pitigliani" Translational Research Unit and Medical Oncology Department, Hospital of Prato, Prato, Italy. Electronic address: luca.malorni@uslcentro.toscana.it.
  • Tyekucheva S; International Breast Cancer Study Group Statistical Center, Department of Data Science, Dana-Farber Cancer Institute and Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address: svitlana@jimmy.harvard.edu.
  • Hilbers FS; Breast International Group, Brussels, Belgium; Department of Molecular Pathology, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands. Electronic address: f.hilbers@nki.nl.
  • Ignatiadis M; Medical Oncology Department, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium. Electronic address: Michail.Ignatiadis@bordet.be.
  • Neven P; Department of Oncology, KU Leuven University Hospitals Leuven Gasthuisberg Campus, Department of Gynecology and Obstetrics and Multidisciplinary Breast Center, UZ-KU Leuven Cancer Institute (LKI), Katholieke Universiteit, Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.
  • Colleoni M; International Breast Cancer Study Group and Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: marco.colleoni@ieo.it.
  • Henry S; Department of Medical Oncology, Hematology, Radiotherapy and Nuclear Medicine, Université Catholique de Louvain, CHU UCL Namur (Site Ste Elisabeth), Namur, Belgium. Electronic address: stephanie.henry@uclouvain.be.
  • Ballestrero A; Department of Internal Medicine and Oncology, IRCCS Ospedale Policlinico San Martino, Genova, Italy. Electronic address: aballestrero@unige.it.
  • Bonetti A; Department of Oncology, AULSS 9 of the Veneto Region, Mater Salutis Hospital, Legnago, VR, Italy. Electronic address: andrea.bonetti@aulss9.veneto.it.
  • Jerusalem G; International Breast Cancer Study Group and CHU Liège, Liège University, Liège, Belgium. Electronic address: g.jerusalem@chuliege.be.
  • Papadimitriou K; Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Antwerp, Belgium. Electronic address: konstantinos.papadimitriou@uza.be.
  • Bernardo A; Medical Oncology Unit, ICS Maugeri-IRCCS, Pavia, Italy. Electronic address: antonio.bernardo@icsmaugeri.it.
  • Seles E; Ospedale Degli Infermi, Ponderano, Italy. Electronic address: elena.seles@aslbi.piemonte.it.
  • Duhoux FP; Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, and Breast Clinic, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Brussels, Belgium. Electronic address: francois.duhoux@uclouvain.be.
  • MacPherson IR; Wolfson Wohl Cancer Research Center, Institute of Cancer Sciences, University of Glasgow, UK. Electronic address: iain.macpherson@glasgow.ac.uk.
  • Thomson A; Royal Cornwall Hospital, Truro UK. Electronic address: alastairthomson1@nhs.net.
  • Davies DM; Department of Oncology, South West Wales Oncology Center, Swansea, UK. Electronic address: Mark.Davies44@wales.nhs.uk.
  • Bergqvist M; Biovica, Uppsala, Sweden. Electronic address: mattias.bergqvist@biovica.com.
  • Migliaccio I; "Sandro Pitigliani" Translational Research Unit, Hospital of Prato, Prato, Italy. Electronic address: ilenia.migliaccio@uslcentro.toscana.it.
  • Gebhart G; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium. Electronic address: Geraldine.gebhart@bordet.be.
  • Zoppoli G; Department of Internal Medicine, Università Degli Studi di Genova and IRCCS Ospedale Policlinico Martino, Genoa, Italy. Electronic address: gabriele.zoppoli@unige.it.
  • Bliss JM; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK. Electronic address: Judith.bliss@icr.ac.uk.
  • Benelli M; Bioinformatics Unit, Hospital of Prato, Prato, Italy. Electronic address: matteo.benelli@uslcentro.toscana.it.
  • McCartney A; "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy; School of Clinical Sciences, Monash University, Melbourne, Australia. Electronic address: amelia.mccartney@uslcentro.toscana.it.
  • Kammler R; International Breast Cancer Study Group, Bern, Switzerland. Electronic address: Rosita.Kammler@ibcsg.org.
  • De Swert H; Breast International Group, Brussels, Belgium. Electronic address: heidi.deswert@bigagainstbc.org.
  • Ruepp B; International Breast Cancer Study Group, Bern, Switzerland. Electronic address: Barbara.Ruepp@ibcsg.org.
  • Fumagalli D; Breast International Group, Brussels, Belgium. Electronic address: Debora.Fumagalli@bigagainstbc.org.
  • Maibach R; International Breast Cancer Study Group, Bern, Switzerland. Electronic address: rudolf.maibach@ibcsg.org.
  • Cameron D; Breast International Group, Brussels, Belgium; Cancer Research UK Edinburgh Center, University of Edinburgh Cancer Research Center, Edinburgh, UK. Electronic address: D.Cameron@ed.ac.uk.
  • Loi S; International Breast Cancer Study Group and Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: sherene.loi@petermac.org.
  • Piccart M; Institut Jules Bordet and L'Universite Libre de Bruxelles, Brussels, Belgium. Electronic address: martine.piccart@bordet.be.
  • Regan MM; International Breast Cancer Study Group Statistical Center, Division of Biostatistics, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. Electronic address: mregan@jimmy.harvard.edu.
Eur J Cancer ; 164: 39-51, 2022 03.
Article en En | MEDLINE | ID: mdl-35172272
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Timidina Quinasa / Neoplasias de la Mama Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Eur J Cancer Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Timidina Quinasa / Neoplasias de la Mama Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Eur J Cancer Año: 2022 Tipo del documento: Article